<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104775</url>
  </required_header>
  <id_info>
    <org_study_id>GNC-035-101（V2.0）</org_study_id>
    <nct_id>NCT05104775</nct_id>
  </id_info>
  <brief_title>A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy</brief_title>
  <official_title>An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Relapsed/Refractory Hematologic Malignancy and Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SystImmune Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients&#xD;
      with relapsed/refractory hematologic malignancies will be investigated to assess the&#xD;
      dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD)&#xD;
      for MTD is not reached of GNC-035.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD or MAD</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Maximum tolerated dose or maximum administrated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TEAE</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Treatment-Emergent Adverse Event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The recommended dose for future clinical study</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>The recommended dose for future clinical study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AESI</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse Events of special interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Maximum serum concentration of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Time to maximum serum concentration (Tmax) of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 2 weeks</time_frame>
    <description>Half-life of GNC-035</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of ADA</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Anti-drug antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of Response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>study treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive GNC-035 as a 24-hour continuous intravenous infusion (cIV, QD) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GNC-035</intervention_name>
    <description>Administration by intravenous infusion.</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The participants could understand and sign the informed consent form, and must&#xD;
             participate voluntarily&#xD;
&#xD;
          2. No gender limit&#xD;
&#xD;
          3. Age: ≥18 and ≤75 years old&#xD;
&#xD;
          4. Life expectancy estimated to be at least 3 months&#xD;
&#xD;
          5. Histologically or cytologically confirmed relapsed or refractory non-Hodgkin's&#xD;
             lymphoma, relapsed/refractory chronic lymphocytic leukemia, relapsed/refractory acute&#xD;
             B-lymphoblastic leukemia, or relapsed/refractory acute myeloid leukemia&#xD;
&#xD;
          6. For relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), specifically:&#xD;
&#xD;
               -  Patients who have relapsed after at least 1 line of standard therapy or who have&#xD;
                  failed or are intolerant to standard therapy;&#xD;
&#xD;
               -  Patients with relapsed or refractory chronic lymphocytic leukemia who, in the&#xD;
                  opinion of the investigator, have none or are not suitable/intolerant to other&#xD;
                  therapies;&#xD;
&#xD;
          7. For other patients with relapsed and refractory non-Hodgkin's lymphoma. These include:&#xD;
&#xD;
               -  Patients in first relapse who still progress during second-line treatment;&#xD;
&#xD;
               -  Patients who relapsed after second-line or multi-line therapy;&#xD;
&#xD;
               -  Refractory patients are defined as those who do not respond or progress after&#xD;
                  adequate dose and full cycle of standard or current commonly selected combination&#xD;
                  therapy regimens, and do not respond or progress after replacement of second-line&#xD;
                  regimens;&#xD;
&#xD;
               -  Relapsed or refractory patients who are judged by the investigator to have no or&#xD;
                  no indication/intolerance to other therapy.&#xD;
&#xD;
          8. Relapsed or refractory acute B-lymphoblastic leukemia, including:&#xD;
&#xD;
               -  Definition of refractory ALL: failure to achieve CR after standard induction&#xD;
                  therapy for bone marrow and peripheral blood response;&#xD;
&#xD;
               -  Relapsed ALL is defined as the presence of blasts (&gt; 5%) in the peripheral blood&#xD;
                  or bone marrow, or the presence of extramedullary disease in patients who have&#xD;
                  achieved CR; mediastinal enlargement in patients who have achieved CR.&#xD;
&#xD;
               -  Special circumstances: There is no clear classification standard for adult ALL&#xD;
                  patients with number of relapse ≥ 2, persistent extramedullary leukemia and&#xD;
                  persistent positive minimal residual disease (MRD). However, most clinical trials&#xD;
                  classified these patients as refractory cases.&#xD;
&#xD;
               -  Patients with relapsed or refractory acute B-lymphoblastic leukemia who, in the&#xD;
                  opinion of the investigator, have no or no indication/intolerance to other&#xD;
                  therapy.&#xD;
&#xD;
          9. Relapsed/refractory acute myeloid leukemia (AML), relapsed/refractory AML is defined&#xD;
             as one of the following:&#xD;
&#xD;
               -  Initial treatment who failed to respond to 2 courses of standard regimen;&#xD;
&#xD;
               -  Patients with relapse within 12 months , consolidation and intensive treatment&#xD;
                  after complete remission;&#xD;
&#xD;
               -  Patients who relapsed after 12 months but failed to respond to conventional&#xD;
                  chemotherapy;&#xD;
&#xD;
               -  Patients with two or more recurrences;&#xD;
&#xD;
               -  Patients with persistent extramedullary leukemia;&#xD;
&#xD;
               -  Patients with relapsed or refractory acute myeloid leukemia who have no or no&#xD;
                  indication/intolerance to other therapy as judged by the investigator.&#xD;
&#xD;
         10. Patients with Philadelphia chromosome positive (Ph +) acute lymphoblastic leukemia are&#xD;
             eligible if they are intolerant or have failed first and/or second generation tyrosine&#xD;
             kinase inhibitors (TKIs); patients with a positive T315I mutation do not require TKI&#xD;
             salvage&#xD;
&#xD;
         11. For non-Hodgkin lymphoma, measurable lesions on CT (any lymph node lesion ≥ 1.5 cm in&#xD;
             long diameter or &gt; 1.0 cm in long diameter for extranodal lesions) at screening;&#xD;
             CLL/SLL: peripheral blood leukemia cells ≥ 5.0 × 109/L; or any lymph node lesion ≥ 1.5&#xD;
             cm in long diameter; WM: IgM 2 × ULN;&#xD;
&#xD;
         12. For patients with acute lymphoblastic leukemia, ≥ 5% lymphoblasts in the bone marrow&#xD;
             by morphologic assessment&#xD;
&#xD;
         13. For patients with acute myeloid leukemia, ≥ 5% blasts in the bone marrow by&#xD;
             morphologic assessment&#xD;
&#xD;
         14. ECOG Performance Status ≤ 2&#xD;
&#xD;
         15. Recovery from toxicities of prior anticancer therapy to ≤ Grade 1 as defined by&#xD;
             NCI-CTCAEv5.0 (except alopecia)&#xD;
&#xD;
         16. The organ function level within 7 days before the first administration meets the&#xD;
             following requirements:&#xD;
&#xD;
             Bone marrow function (only for patients with non-Hodgkin's lymphoma): Neutrophils&#xD;
             without blood transfusion, G-CSF (without long-acting whitening needles within 2&#xD;
             weeks) and drug correction within 7 days before screening Absolute count (ANC)&#xD;
             ≥1.0×10^9/L (for subjects with bone marrow infiltration, ≥0.5×10^9/L); hemoglobin ≥80&#xD;
             g/L (for subjects with bone marrow infiltration, ≥70g /L); Platelet count ≥50×10^9/L;&#xD;
             Liver function: In the case of no hepatoprotective drugs for correction within 7 days&#xD;
             before screening, total bilirubin ≤ 1.5 ULN (Gilbert's syndrome ≤ 3 ULN), transaminase&#xD;
             (AST/ALT) ≤ 2.5 ULN (tumor invasive changes in the liver) Subject ≤5.0 ULN), and/or&#xD;
             alkaline phosphatase ≤5 ULN; Kidney function: creatinine (Cr) ≤ 1.5 ULN or creatinine&#xD;
             clearance (Ccr) ≥ 50 mL/min (calculated by the research center); Coagulation function:&#xD;
             fibrinogen ≥ 1.5g/L; activated partial thromboplastin time (APTT) ≤ 1.5 × ULN;&#xD;
             prothrombin time (PT) ≤ 1.5 × ULN;&#xD;
&#xD;
         17. Female participants with fertility or male participants whose partner(s) are fertile&#xD;
             must take effective contraceptive measures from 7 days prior to the first&#xD;
             administration to 12 weeks after the administration. Female participants with&#xD;
             fertility must have a negative serum/urine pregnancy test in 7 days prior to the first&#xD;
             dose.&#xD;
&#xD;
         18. Subjects are capable and willing to comply with the visits, treatment plans,&#xD;
             laboratory examinations and other research-related procedures stipulated in the&#xD;
             research protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have undergone major surgery within 28 days prior to dosing in this&#xD;
             study, or are scheduled to undergo major surgery during this study (&quot;major surgery&quot;is&#xD;
             defined by the investigator)&#xD;
&#xD;
          2. Pulmonary disease ≥ grade 3 according to NCI-CTCAEv5.0: including resting dyspnea, or&#xD;
             requiring continuous oxygen therapy; patients with current interstitial lung disease&#xD;
             (ILD) (except for those with previous interstitial pneumonia)&#xD;
&#xD;
          3. Systemic serious infections occurred within 4 weeks before screening，including but not&#xD;
             limited to severe pneumonia, bacteremia or serious infectious complications caused by&#xD;
             fungi, bacteria and viruses&#xD;
&#xD;
          4. Patients with active autoimmune diseases, or patients with a history of autoimmune&#xD;
             diseases&#xD;
&#xD;
          5. Patients complicated with other malignant tumors within 5 years before the first dose,&#xD;
             and cured non-melanoma in situ skin cancer, superficial bladder cancer, in situ&#xD;
             cervical cancer, gastrointestinal intramucosal cancer, breast cancer, localized&#xD;
             prostate cancer and other cancers that are considered by the investigator to be&#xD;
             eligible&#xD;
&#xD;
          6. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active&#xD;
             hepatitis B virus infection (positive HBsAg or positive HBcAb with HBV-DNA ≥ ULN), or&#xD;
             hepatitis C virus infection (positive HCV antibody with HCV-RNA ≥ ULN)&#xD;
&#xD;
          7. Hypertension poorly controlled on medication (systolic &gt; 150 mmHg or diastolic &gt; 100&#xD;
             mmHg)&#xD;
&#xD;
          8. Left ventricular ejection fraction ≤ 45%, or history of significant cardiac disease&#xD;
             within 1 year&#xD;
&#xD;
          9. Patients with a history of hypersensitivity to recombinant humanized antibodies or&#xD;
             hypersensitivity to any of the excipient components of GNC-035&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding&#xD;
&#xD;
         11. Previous or concomitant central nervous system disease&#xD;
&#xD;
         12. With CNS involvement&#xD;
&#xD;
         13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation&#xD;
             (ALLo-HSCT)&#xD;
&#xD;
         14. Autologous hematopoietic stem cell transplantation (Auto-HSCT) was performed 12 weeks&#xD;
             before starting GNC-035 treatment&#xD;
&#xD;
         15. Are using immunosuppressive agents, including but not limited to: Cyclosporine,&#xD;
             tacrolimus, etc. within 2 weeks before GNC-035 treatment; High-dose glucocorticoids&#xD;
             (longer than 14 days) within 2 weeks before GNC-035 treatment , A daily stable dose of&#xD;
             &gt;30mg of prednisone or the same dose of other glucocorticoids);&#xD;
&#xD;
         16. Radiotherapy 4 times before starting GNC-035 treatment; chemotherapy and small&#xD;
             molecule targeted drugs 2 weeks before treatment&#xD;
&#xD;
         17. CD19 or anti-CD22 treatment and still respond, received Amgen Belintotumomab&#xD;
             (CD19×CD3), inotuzumab-oxazomicin (CD22-ADC) treatment within 4 weeks before&#xD;
             treatment;&#xD;
&#xD;
         18. Received CAR-T 12 weeks prior to starting GNC-035&#xD;
&#xD;
         19. Has receivedany other clinical trial within 4 weeks prior to GNC-035 treatment&#xD;
&#xD;
         20. The investigator believes that it is not suitable to participate in other situations&#xD;
             in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ruijin Hospital of Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weili Zhao</last_name>
      <phone>+86-13512112076</phone>
      <email>zwl_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Weili Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Acute B-lymphoblastic Leukemia</keyword>
  <keyword>Relapsed/Refractory Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

